Bepreve FDA Approval History
FDA Approved: Yes (First approved September 8, 2009)
Brand name: Bepreve
Generic name: bepotastine
Dosage form: Ophthalmic Solution
Company: ISTA Pharmaceuticals, Inc.
Treatment for: Conjunctivitis, Allergic
Bepreve (bepotastine ophthalmic solution) is an antihistamine and mast cell stabilizer for treatment of the symptoms of allergic conjunctivitis.
Development Timeline for Bepreve
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.